Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective.

Oo C, Sy SKB.

Drug Discov Today. 2019 Sep 6. pii: S1359-6446(19)30336-8. doi: 10.1016/j.drudis.2019.07.012. [Epub ahead of print] No abstract available.

PMID:
31499189
2.

A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases.

Oo C, Noveck RJ.

Ther Innov Regul Sci. 2019 May 9:2168479019845667. doi: 10.1177/2168479019845667. [Epub ahead of print] No abstract available.

PMID:
31072122
3.

Orthogonal Stimulus-Response as a Tool to Formulate Traditional Chinese Medicinal Herbal Combination: - New Scientific-Based TCM Herbal Formulating Method.

Loh YC, Tan CS, Yam MF, Oo CW, Omar WMW.

J Pharmacopuncture. 2018 Sep;21(3):203-206. doi: 10.3831/KPI.2018.21.024. Epub 2018 Sep 30.

4.

New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases.

Win S, Than TA, Zhang J, Oo C, Min RWM, Kaplowitz N.

Hepatology. 2018 May;67(5):2013-2024. doi: 10.1002/hep.29689. Epub 2018 Apr 6. Review.

5.

Fixed-dose combinations: a potential means to boost drug development for selected drugs.

Oo C, Sy SKB.

Drug Discov Today. 2018 Mar;23(3):457-459. doi: 10.1016/j.drudis.2017.11.001. Epub 2017 Nov 14. No abstract available.

PMID:
29146518
6.

Erratum to: Detection of Schistosoma Antibodies and exploration of associated factors among local residents around Inlay Lake, Southern Shan State, Myanmar.

Soe HZ, Oo CC, Myat TO, Maung NS.

Infect Dis Poverty. 2017 Jul 13;6(1):118. doi: 10.1186/s40249-017-0334-y. No abstract available.

7.
8.

Proposed Strategies for the Integration of Genomics in Primary Care.

Oo C, Noveck RJ.

Am J Med. 2016 Jul;129(7):e87. doi: 10.1016/j.amjmed.2016.01.025. No abstract available.

PMID:
27320714
9.

QT Correction: Using an Observed Regression Factor Applicable to a Population Subset.

Oo C, Kalbag SS.

J Pharm Pharm Sci. 2016;19(1):25-30. doi: 10.18433/J39G77.

10.

Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development.

Oo C, Kalbag SS.

Expert Rev Clin Pharmacol. 2016 Jun;9(6):747-9. doi: 10.1586/17512433.2016.1160778. Epub 2016 Mar 16. No abstract available.

PMID:
26933755
11.

A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

Oo C, Rusch LM.

J Clin Pharmacol. 2016 Mar;56(3):257-9. doi: 10.1002/jcph.599. Epub 2015 Sep 18. No abstract available.

PMID:
26211513
12.

There is no better time than the present: nanotechnology as a disruptive innovation for drug development.

Oo C, Tsai JC, Kao HD.

Drug Discov Today. 2015 Jun;20(6):645-7. doi: 10.1016/j.drudis.2015.03.013. Epub 2015 Mar 31. No abstract available.

PMID:
25835226
13.

Can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?

Oo C, Duchin KL.

Clin Pharmacol Ther. 2014 May;95(5):489. doi: 10.1038/clpt.2014.6. Epub 2014 Jan 10. No abstract available.

PMID:
24518656
14.

In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver.

Igawa Y, Fujitani T, Shah B, Oo C, Kanai Y.

Xenobiotica. 2014 Jan;44(2):154-63. doi: 10.3109/00498254.2013.865857. Epub 2013 Dec 4.

PMID:
24304169
15.

Not wasted time in aged care placement.

Oo CC.

Aust Nurs J. 2013 Jun;20(11):4. No abstract available.

PMID:
23862328
16.
17.

9-(7-Fluoro-4-oxo-4H-chromen-3-yl)-3,3,6,6-tetra-methyl-2,3,4,5,6,7,8,9-octa-hydro-1H-xanthene-1,8-dione.

Asad M, Oo CW, Osman H, Fun HK, Arshad S.

Acta Crystallogr Sect E Struct Rep Online. 2012 Jan;68(Pt 1):o38. doi: 10.1107/S1600536811051749. Epub 2011 Dec 7.

18.

Does erythromycin have anti-inflammatory effects independent of its antimicrobial action?

Oo C, Shah B.

J Clin Pharmacol. 2012 Apr;52(4):613-4. doi: 10.1177/0091270011398245. Epub 2011 Aug 25. No abstract available.

PMID:
21868717
19.

3-Hydroxy-2-[(2-hydroxy-4,4-dimethyl-6-oxocyclohex-1-en-1-yl)(thiophen-3-yl)methyl]-5,5-dimethylcyclohex-2-en-1-one.

Asad M, Oo CW, Osman H, Rosli MM, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2011 Jul 1;67(Pt 7):o1813. doi: 10.1107/S160053681102407X. Epub 2011 Jun 25.

20.

2-[(E)-(2,4-Dichloro-benzyl-idene)amino]-isoindoline-1,3-dione.

Asad M, Oo CW, Osman H, Hemamalini M, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2011 Jul 1;67(Pt 7):o1712. doi: 10.1107/S1600536811023063. Epub 2011 Jun 18.

21.

4-Hy-droxy-3-[(4-hy-droxy-2-oxo-2H-3-chromen-yl)(3-thien-yl)meth-yl]-2H-chromen-2-one.

Asad M, Oo CW, Osman H, Rosli MM, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2011 May 1;67(Pt 5):o1037-8. doi: 10.1107/S1600536811011676. Epub 2011 Apr 7.

22.

7-Fluoro-4-oxochromene-3-carbaldehyde.

Asad M, Oo CW, Osman H, Hemamalini M, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2011 Apr 1;67(Pt 4):o766. doi: 10.1107/S1600536811007045. Epub 2011 Mar 2.

23.

4-Hy-droxy-3-[(4-hy-droxy-6-methyl-2-oxo-3,6-dihydro-2H-pyran-3-yl)(3-thien-yl)meth-yl]-6-methyl-3,6-dihydro-2H-pyran-2-one.

Asad M, Oo CW, Osman H, Hemamalini M, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2011 Jan 26;67(Pt 2):o494-5. doi: 10.1107/S1600536811002716.

24.

3-[5-(2,4-Dichloro-phen-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]-4-hy-droxy-2H-chromen-2-one.

Asad M, Oo CW, Osman H, Rosli MM, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2011 Jan 22;67(Pt 2):o437-8. doi: 10.1107/S1600536811001590.

25.

3-Acetyl-4-hy-droxy-6,7-dimethyl-2H-chromen-2-one.

Asad M, Oo CW, Osman H, Goh JH, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2010 Nov 13;66(Pt 12):o3129-30. doi: 10.1107/S1600536810045010.

26.

3-[(E)-3-(2,4-Dichloro-phen-yl)prop-2-en-oyl]-4-hy-droxy-2H-chromen-2-one.

Asad M, Oo CW, Osman H, Quah CK, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2010 Oct 31;66(Pt 11):o3022-3. doi: 10.1107/S1600536810043837.

27.

3-Methyl-4-[(E)-3-thien-ylmethyl-idene-amino]-1H-1,2,4-triazole-5(4H)-thione.

Asad M, Oo CW, Osman H, Yeap CS, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2010 Oct 20;66(Pt 11):o2861-2. doi: 10.1107/S1600536810041152.

28.

4-Hy-droxy-3-[(4-hy-droxy-6,7-dimethyl-2-oxo-2H-chromen-3-yl)(4-oxo-4H-chromen-3-yl)meth-yl]-6,7-dimethyl-2H-chromen-2-one.

Asad M, Oo CW, Osman H, Yeap CS, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2010 Oct 20;66(Pt 11):o2859-60. doi: 10.1107/S1600536810041231.

29.

4-[(E)-(4-Hy-droxy-2-oxo-2H-chromen-3-yl)methyl-idene-amino]-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one monohydrate.

Asad M, Oo CW, Osman H, Quah CK, Fun HK.

Acta Crystallogr Sect E Struct Rep Online. 2010 Sep 4;66(Pt 10):o2491-2. doi: 10.1107/S160053681003480X.

30.
31.

Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan.

Mondick JT, Oo C, Patel D, Fujitani T, Shimizu K, Barrett JS.

Am J Ther. 2009 Mar-Apr;16(2):106-15. doi: 10.1097/MJT.0b013e31816b8c85.

PMID:
19300037
32.

The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.

Oo C, Chen YC.

J Clin Pharmacol. 2009 Mar;49(3):368-9; author reply 370. doi: 10.1177/0091270008325931. No abstract available.

PMID:
19246734
33.

Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

Kurowski M, Oo C, Wiltshire H, Barrett J.

Clin Drug Investig. 2004;24(1):49-53. No abstract available.

PMID:
17516690
34.

Reciprocating dialysis tube method: periodic tapping improved in vitro release/dissolution testing of suppositories.

Itoh S, Teraoka N, Matsuda T, Okamoto K, Takagi T, Oo C, Danny Kao H.

Eur J Pharm Biopharm. 2006 Nov;64(3):393-8. Epub 2006 Jun 28.

PMID:
16890412
35.

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.

Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P.

Eur J Clin Pharmacol. 2003 Sep;59(5-6):411-5. Epub 2003 Aug 9.

PMID:
12910331
36.

Safety and pharmacology of oseltamivir in clinical use.

Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P.

Drug Saf. 2003;26(11):787-801. Review.

PMID:
12908848
37.

Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.

Oo C, Snell P, Barrett J, Dorr A, Liu B, Wilding I.

Int J Pharm. 2003 May 12;257(1-2):297-9.

PMID:
12711184
38.

A comparative study of three warming interventions to determine the most effective in maintaining perioperative normothermia.

Ng SF, Oo CS, Loh KH, Lim PY, Chan YH, Ong BC.

Anesth Analg. 2003 Jan;96(1):171-6, table of contents.

PMID:
12505947
39.
40.

Change in creatinine clearance with advancing age.

Oo C, Liu B, Hill G.

J Am Geriatr Soc. 2002 Sep;50(9):1603-4. No abstract available.

PMID:
12383168
41.

Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.

Oo C, Barrett J, Dorr A, Liu B, Ward P.

Antimicrob Agents Chemother. 2002 Jun;46(6):1993-5.

42.

Speechless after bone marrow transplantation: a rare complication of parainfluenza virus related group in an adult.

Au WY, Tsang TY, Lie AK, Yuen KY, Oo CG, Liang R, Kwong YL.

Leuk Lymphoma. 2002 Feb;43(2):421-2.

PMID:
11999579
43.

Active transport of nitrofurantoin into rat milk.

Oo CY, Paxton EW, McNamara PJ.

Adv Exp Med Biol. 2001;501:547-52.

PMID:
11787727
44.

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P.

Drug Metab Dispos. 2002 Jan;30(1):13-9.

PMID:
11744606
45.

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.

Oo C, Barrett J, Hill G, Mann J, Dorr A, Dutkowski R, Ward P.

Paediatr Drugs. 2001;3(3):229-36. Erratum in: Paediatr Drugs 2001;3(4):246.

PMID:
11310719
46.

Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk.

Gerk PM, Oo CY, Paxton EW, Moscow JA, McNamara PJ.

J Pharmacol Exp Ther. 2001 Jan;296(1):175-80.

PMID:
11123378
47.

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.

Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, Buss N, Saag MS.

Antimicrob Agents Chemother. 2000 Oct;44(10):2672-8.

48.

Clonazepam and sertraline: absence of drug interaction in a multiple-dose study.

Bonate PL, Kroboth PD, Smith RB, Suarez E, Oo C.

J Clin Psychopharmacol. 2000 Feb;20(1):19-27.

PMID:
10653204
49.

Active transport of cimetidine into human milk.

Oo CY, Kuhn RJ, Desai N, McNamara PJ.

Clin Pharmacol Ther. 1995 Nov;58(5):548-55.

PMID:
7586949
50.

Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk.

Oo CY, Kuhn RJ, Desai N, Wright CE, McNamara PJ.

Br J Clin Pharmacol. 1995 Sep;40(3):231-6.

Supplemental Content

Support Center